Earth.com

Vaccine safety study includes 99 million people

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Tracking health across a lifetime: Northern Finland Birth Cohort 1966 launches new follow-up as participants turn 60

One of the world's most extensive birth cohorts is now entering later adulthood. At the University of Oulu in Finland, the ...
Business Wire

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
European Medical Journal

MDMA-Assisted Therapy Shows Sustained Benefits in Depression

MDMA-assisted therapy may provide lasting benefit for patients with MDD. Seven-month follow-up shows sustained symptom ...
STAT

Addressing the “postpartum cliff” may be as simple as sending a few text messages

Most pregnant people are in regular touch with their maternity care providers over the course of nine months, with ever-more-frequent visits, tests, and scans as their due date nears. For many ...
Medscape

Study Supports Follow-Up Consultations After Heart Failure

About 40% of patients with diagnosed heart failure did not pursue future cardiology consultations, regardless of the initial severity of their condition. A single ...
The American Journal of Managed Care

Timely Outpatient Follow-Up Reduces Hospital Readmissions

Adequate outpatient follow-up within 30 days significantly reduces 30-day all-cause hospital readmissions, impacting hospital finances and patient care quality. The study analyzed 83 studies, ...
Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...